NEW YORK — Researchers say that an old drug called salmeterol could prevent the development of skin cancer in mice.
The drug is called Nizatriptan and is approved to treat certain cancers, but some people are worried that it can cause side effects and be difficult to use.
So researchers at the New York University Langone Medical Center in New York City have developed a new drug called Nitzatriptin, which they say is safe and well tolerated.
Nizatryptan is used to treat patients with type 1 diabetes, a disorder that causes blood sugar levels to fall and the body’s immune system attacks the cells that normally fight off cancer cells.
A previous study showed that Nitzon, also known as Nexium, could be used to reduce blood sugar in patients with advanced melanoma.
Nitzatryptans efficacy in mice was first shown in 2012.
The drug was given to mice with melanoma and found that it stopped the progression of the disease.
Researchers say that the drug’s combination of antifungals and anti-inflammatory properties have the potential to prevent the progression in melanoma cells.
The researchers say the drug also helps to prevent cancer cells from growing.
“The combination of anti-tumor agents and immunosuppressants are the key to this discovery,” said Dr. Matthew C. Stangland, the lead author of the study published in the journal Science.
Stangland said that Niztriptan’s combination with antifundacy drugs such as methotrexate and diclofenac may be the key ingredient that makes it effective in the treatment of melanoma in mice, and may have the ability to treat cancer in humans.
The researchers are now developing Nitzaton, which is approved by the U.S. Food and Drug Administration for use in melanomas.
The company plans to begin a clinical trial in 2020 to test whether Nitzotriptan can be used safely and effectively in humans in a clinical setting.